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A B S T R A C T
Triapine is an a-N-heterocyclic thiosemicarbazone with promising anticancer activity against
hematologic malignancies but widely ineffective against solid tumor types in clinical trials. The
anticancer activity of thiosemicarbazones can be dramatically increased by terminal dimethylation.
KP1089 is a gallium compound containing two terminal dimethylated thiosemicarbazone ligands. To
gain insights on the vulnerability of this highly active terminal dimethylated thiosemicarbazone to
drug resistance mechanisms, a new cell model with acquired resistance against the lead compound
KP1089 was established. Subsequent genomic analyses (arrayCGH and FISH) revealed ampliﬁcation of
the ABCC1 gene on double minute chromosomal DNA in KP1089-resistant cells as well as
overexpression of ABCC1 and ABCG2 on the protein level. KP1089 was further conﬁrmed as a
substrate of ABCC1 and ABCG2 but not of ABCB1 using a panel of ABC transporter-overexpressing cell
models as well as ABC transporter inhibitors. Moreover, glutathione depletion strongly enhanced
KP1089 activity, although no glutathione conjugate formation by glutathione-S-transferase was
observed. Thus, a co-transport of KP1089 together with glutathione is suggested. Finally, a panel of
thiosemicarbazone derivatives was tested on the new KP1089-resistant cell line. Notably, KP1089-
resistant cells were not cross-resistant against thiosemicarbazones lacking terminal dimethylation
(e.g. Triapine) which are less active than KP1089. This suggests that terminal dimethylation of
thiosemicarbazones – linked with distinctly enhanced anticancer activity – leads to altered resistance
proﬁles compared to classical thiosemicarbazones making this compound class of interest for further
(pre)clinical evaluation.
 2012 Elsevier Inc. 
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The promising anticancer activity of thiosemicarbazone-based
drugs is well known and resulted in the clinical development of the
ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxal-
dehyde thiosemicarbazone (Triapine, Fig. 1). Indeed, several
studies already proofed the activity of Triapine against advanced
leukemia in clinical phase I trials [1,2]. However, several clinical
phase II studies revealed that Triapine is ineffective against a
variety of solid tumors including advanced adenocarcinoma of the
pancreas [3], non-small-cell lung cancer [4], and renal cell
carcinoma [5]. Although an impact of multidrug-resistance
proteins (especially of ABCB1) was already suggested [6–8], the
reasons for the general inefﬁcacy of Triapine against solid tumors
are widely speculative. In general, the mechanisms of drug
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Fig. 1. The structures of KP1089 and other relevant thiosemicarbazones.
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only on one mechanism but is found to be multifaceted and
complex. Thus, resistance at the cellular level might be, on the one
hand, directly associated with the mode of action of the respective
anticancer agent (such as changed target expression or target
mutation). On the other hand, tumors frequently develop cross-
resistance to several, often structurally and mechanistically
unrelated drugs, a phenomenon called multidrug resistance
(MDR) [9]. One of the most prominent and best investigated
mechanisms underlying MDR is the (over)expression of ATP-
driven membrane-located export proteins, so called ABC trans-
porters. In humans, 49 members of the ABC transporter family
have been described. However, only a few are involved in drug
efﬂux, namely ABCB1 (P-glycoprotein; P-gp), several members of
the ABCC subfamily (multidrug-resistance protein; MRP), espe-
cially ABCC1 and ABCC2, as well as ABCG2 (breast cancer resistance
protein; BCRP). In general, the substrate speciﬁcity of MDR-
conferring ABC transporters overlaps. Consequently, some com-
pounds are substrates for several ABC transporters (e.g. doxorubi-
cin or etoposide, which are transported by ABCB1, ABCC1 as well as
ABCG2 [10]).
To enhance the anticancer activity of Triapine, the develop-
ment of thiosemicarbazone derivatives with altered pharmaco-
logical characteristics is of interest. Additionally, such new
derivatives can be used to gain more insights into the structural
characteristics underlying the resistance against Triapine. We
have recently reported the synthesis of novel gallium complexes
containing a-N-heterocyclic thiosemicarbazone ligands [11,12].
These studies revealed that, in the absence of a NH2 group in the
molecule, dimethylation of the terminal nitrogen strongly
enhanced the cytotoxicity of a-N-heterocyclic thiosemicarba-
zones and their metal-containing complexes (e.g. the gallium
complex KP1089) by about 1000-fold. Moreover, the increased
cytotoxicity was found to be only partly dependent on the
ribonucleotide reductase inhibitory ability of these new com-
pounds implying that other yet unknown mechanisms are
involved [12]. To gain more insights into the mode of action as
well as to evaluate the vulnerability of terminal dimethylated a-
N-heterocyclic thiosemicarbazones to drug resistance mecha-
nisms, a new cell model with acquired resistance against the
model substance KP1089 was established (Fig. 1). Our studies
revealed that, in contrast to Triapine and other thiosemicarba-
zones which lack terminal dimethylation (TD), resistance against
KP1089 (and other terminal dimethylated thiosemicarbazones) is
mediated by the GSH conjugate transporter ABCC1 and the drug
transporter ABCG2.2. Materials and methods
2.1. Drugs
[Bis(2-acetylpyridine 4,4-dimethylthiosemicarbazonato-N,N,S)
gallium(III)] tetrachloridogallat (KP1089), 3-aminopyridine-2-
carboxaldehyde thiosemicarbazone (Triapine), 2-acetylpyridine
4,4-dimethylthiosemicarbazone (KP1550), [bis(2-acetylpyridine
thiosemicarbazonato-N,N,S)gallium(III)] nitrat (KP1657), [bis(3-
aminopyridine-2-carboxaldehyde 4,4-dimethylthiosemicarbazo-
nato-N,N,S)gallium(III)] hexaﬂuorophosphate (KP1719), [bis(2-
formylpyridine 4,4-dimethylthiosemicarbazonato-N,N,S)galliu-
m(III)] hexaﬂuorophosphate (KP1740), were prepared as described
previously [11–13]. The compounds were dissolved in DMSO and
diluted into the culture media at the concentrations indicated
(DMSO concentrations were always below 0.1%). Verapamil was
purchased from Abbott (Vienna, Austria), cyclosporin A from Sandoz
(Basel, Switzerland), BCNU from Bristol-Myers Squibb (Munich,
Germany), paclitaxel from Rhone-Poulenc RORER (Essex, GB),
gallium nitrate octahydrate from Merck (Darmstadt, Germany).
All other substances were purchased from Sigma–Aldrich (Vienna,
Austria). All solutions were freshly prepared before usage.
2.2. Cell culture
The following human cell lines and their chemoresistant
sublines were used in this study [14,15]: the epidermal carcino-
ma-derived cell line KB-3-1 and its ABCB1-overexpressing subline
KBC-1 (generously donated by D.W. Shen, Bethesda, USA) [16]; the
promyelocytic leukemia cell line HL60 and its ABCC1-overexpres-
sing subline HL60/adr (from M. Center, Kansas State University,
USA), the small cell lung carcinoma cell line GLC-4 and its ABCC1-
and LRP-overexpressing subline GLC-4/adr (from E.G. deVries,
Groningen, The Netherlands); the breast adenocarcinoma cell line
MDA-MB-231 with its respective ABCG2(R482T)-transfected sub-
clone MDA-MB-231/bcrp (from D. Ross, University of Maryland,
Greenbaum Cancer Centre, USA), the non-small cell lung carcino-
ma cell line SW1573 with its ABCC1- and LRP-overexpressing
subline 2R120 as well as its ABCB1- and ABCC1-overexpressing
subline 2R160 (H. Broxterman, Department of Medical Oncology,
Free University Hospital, Amsterdam, The Netherlands). The ABC
transporter expression levels of the used cell lines were checked by
Western blotting (Fig. S1). All cell lines were grown in RPMI 1640
supplemented with 10% fetal bovine serum with the exception of
SW1573 cells, which were grown in DMEM with 10% serum.
Cultures were regularly checked for Mycoplasma contamination.
2.3. Cytotoxicity assays
Cells were plated (2  103 cells/well for KB, MDA-MB-231,
SW1573 cells; 5  103 cells/well for HL60 cells, and 4  103 cells/
well for GLC-4, 2R120, and 2R160 cells) in 100 ml per well in 96-well
plates. After a recovery period of 24 h, drugs were added in another
100 ml growth medium and cells were exposed for 72 h. The
proportion of viable cells was determined by MTT assay following
the manufacturer’s recommendations (EZ4U, Biomedica, Vienna,
Austria). Cytotoxicity was calculated using the Graph Pad Prism
software (La Jolla, USA) (using a point-to-point function) and was
expressed as IC50 values calculated from full dose-response curves
(drug concentrations inducing a 50% reduction of cell number in
comparison to untreated control cells cultured in parallel).
2.4. Western blot analyses
Cell fractionation, protein separation and Western blotting
were performed as described [17]. The following antibodies were
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dilution: 1:100; anti-LRP monoclonal mouse clone 42 (Transduc-
tion Lab., Lexington, USA), 1:1000; anti-BCRP monoclonal mouse
MAB4146 (Chemicon, Temicola, USA), 1:500, anti-MRP1 monoclo-
nal rat MRPr1 (Sanbio, Uden, The Netherlands), 1:40; anti-MRP2
monoclonal mouse C250 (Alexis Corp., Lausen, Switzerland), 1:50;
anti-MRP3 monoclonal mouse M3II-9 (Alexis Corp., Lausen,
Switzerland), 1:40. All secondary, peroxidase-labeled antibodies
from Szabo-Scandic were used at working dilutions of 1:10,000.
2.5. Cytogenetic analyses
Genomic DNA was isolated using the QIAamp DNA Blood Mini
Kit (Qiagen GmbH, Austria) following the manufacturer’s instruc-
tions. Comparative genomic hybridization (CGH), ﬂuorescence in
situ hybridization (FISH) were performed as described previously
[18,19]. For DNA ampliﬁcation, linker–adapter PCR was used as
described [18]. For the detection of the MRP1 locus the BAC clone
CTD-2504F3 supplied by Sanger Institute (Hinxton, Cambridge,
UK) was used.
2.6. ArrayCGH (aCGH) analyses
aCGH was performed using 4  44 K human whole genome
oligonucleotide-based arrays (Agilent Technologies O¨sterreich
GmbH, Austria) as published [20]. Labeling and hybridization
procedures were done according to the instructions provided by
Agilent. Brieﬂy, 500 ng of tumor DNA and reference DNA (human
male genomic DNA, Promega Corporation, Madison, USA) were
digested with AluI and RsaI (both from Promega), then differen-
tially labeled by random priming with cyanine 5- and cyanine 3-
dUTP (Perkin-Elmer, MA, USA), respectively, using the BioPrime
Array CGH Genomic Labeling Kit (Life Technologies Corporation,
Invitrogen, Paisley, UK). After puriﬁcation with Amicon Ultra
Centrifugal Filters (MILLIPORE GmbH, Vienna, Austria) the two
labeled products together with blocking agent, Hybridization
Buffer (both included in the Oligo aCGH/Chip-on-Chip Hybridiza-
tion Kit, Agilent Technologies), and human cot-DNA (Roche Austria
GmbH, Vienna, Austria) were combined and hybridized onto
4  44 K oligonucleotide arrays. Hybridization was carried out for
48 h at 65 8C in a hybridization oven. Afterwards, slides were
washed according to the protocol and scanned with a G2505B
Micro Array Scanner (Agilent Technologies). Feature extraction
and data analyses were carried out using the Feature Extraction
(version 10.7.3.1) and DNA Analytics software (version 4.0.81),
respectively.
2.7. Binding of KP1550 to GSH
A solution containing 1-chloro-2,4-dinitrobenzene (CDNB;
100 mM in DMF) or KP1550 (100 mM in DMF) and GSH (100 mM
in H2O) was incubated with 1.7 units glutathione-S-transferase
(GST from equine liver; 1 unit conjugates 1.0 mmol of CDNB with
GSH per min) in NaHCO3 buffer pH 6.5 for 1 h at 37 8C. The samples
were centrifuged using Amicon Ultra Centrifugal Filters with a 10 K
membrane to separate the protein and the solutions were
measured by electrospray ionization mass spectrometry (ESI-
MS; Bruker esquire3000 ion trap mass spectrometer).
2.8. Quantiﬁcation of the intracellular GSH levels
Glutathione (98%) and glutathione–glycine–13C2,15N (GSH IS)
standards were purchased from Sigma Aldrich, Vienna, Austria.
Stock solutions containing 1 g/L GSH and the working solutions
were prepared daily in ultrapure water. Cell extracts were diluted
1:100 prior to measurement. For LC–MS measurements a CapillaryPump 1100 series, an m-wellplate sampler and a column oven
from Agilent Technologies were used. For separation a
150 mm  2.1 mm ZIC-HILIC column (3.5 mm particle size)
equipped with a 20 mm  2.1 mm ZIC-HILIC guard column
(5 mm particle size) from Merck, Darmstadt, Germany was used.
LC–MS conditions were as follows: ﬂow rate: 100 mL/min;
injection volume: 5 mL, column temperature: 45 8C. For the
gradient eluent A (98% (v/v) water, 1% (v/v) ACN, 1% (v/v) formic
acid) and eluent B (98% (v/v) ACN, 1% (v/v) water, 1% (v/v) formic
acid) were used according to the following timetable: 60% B for
3 min, followed by a reduction of B to 10% within 5 min,
reconstitution of the starting conditions (60% B) within 1 min
and re-equilibration at the starting conditions for 10 min. Total
analysis time: 19 min. For MS ion trap detection an Agilent 6430
Ion Trap together with an ESI source from Agilent Technologies
was used. Source parameters were as follows: positive ionization
mode, MS–MS mode (drying gas temperature 350 8C, drying gas
ﬂow 10 L/min, nebulizer pressure 25 psi and capillary voltage
4000 V.
2.9. Calcein-AM efﬂux assays
Cells were trypsinised and incubated as single cell suspensions
(3  105 cells/sample) in serum-containing medium with the
known ABCC1 inhibitor cyclosporin A (1 mM) for 30 min at
37 8C. Then the ﬂuorescent ABCC1 substrate calcein-AM
(0.25 mM) was added and the samples were incubated for another
30 min. Subsequently, cells were analyzed by ﬂow cytometry with
an excitation of 494 nm and an emission of 517 nm bandpass ﬁlter.
2.10. Pheophorbide A (PhA) efﬂux assays
Cells were trypsinised and incubated as single cell suspensions
(3  105 cells/sample) in serum-containing medium with the
known ABCG2 inhibitor fumitremorgin C (10 mM) for 30 min at
37 8C. Then the chlorophyll catabolite PhA (10 mM) was added and
the samples were incubated for another hour. Cells were washed in
cold medium and analyzed by ﬂow cytometry with a 488 nm argon
laser and a 585 nm bandpass ﬁlter [21].
3. Results
3.1. Selection of a KP1089-resistant cell model and characterization of
the cross-resistance proﬁle
The KP1089-resistant KB cell line was generated by continuous
exposure of KB-3-1 cells to increasing concentrations of KP1089
(starting point 0.25 nM; end point 50 nM) over a period of one
year. The gallium compound was administered to KB-3-1 cells
twice a week at the day after passage, when cells had attached to
the culture ﬂasks. KP1089-resistant cells were termed KB-
1089(50 nM) and displayed a more than 20-fold resistance to
the selection drug (Table 1, Fig. 2A) as compared to the parental cell
line. As shown in Table 1, KB-1089(50 nM) cells were distinctly
cross-resistant to several (natural) chemotherapeutics including
vincristine (16-fold), anthracyclines (6-fold), as well as etopo-
side (4.6-fold). No cross-resistance to taxol, the alkylating agents
BCNU and temozolomide, or to platinum drugs was observed.
Moreover, KB-1089(50 nM) cells were collaterally sensitive to the
topoisomerase I inhibitor camptothecin (0.6-fold) as well as to the
ribonucleotide reductase inhibitors hydroxyurea (0.5-fold), and
gallium nitrate (0.6-fold). In addition, the KP1089-resistant cell
line was found to be especially sensitive (0.1-fold) to depletion of
the intracellular GSH levels by the gamma-glutamylcysteine
synthetase inhibitor buthionine sulfoximine (BSO). In contrast,
no difference in sensitivity to the glutathione-S-transferase
Table 1
Cross-resistance pattern of KB-1089(50 nM) cells: cancer chemotherapeutics and GSH-modifying drugs. The signiﬁcance of resistance in comparison to the parental line has
been calculated by Student’s t-test using Graph Pad Prism Software.
Drug KB-3-1 KB-1089(50 nM)
IC50 SD IC50 SD Relative resistance
KP1089 (nM) 4.9 0.8 100 – 20-fold*
Vincristine (nM) 1.1 0.6 17.85 0.2 16-fold*
Adriamycin (nM) 36.8 0.9 250 – 7-fold*
Daunomycin (mM) 24.0 1.2 150 – 6-fold*
Etoposide (nM) 0.5 0.01 2.3 1.2 4.6-fold
Taxol (nM) 4.8 0.03 4.9 0.06 1-fold
BCNU (mM) 9.7 2.0 13.3 4.0 1-fold
Temozolomide (mM) 0.45 0.06 0.64 1.3 1-fold
Cisplatin (mM) 1.9 0.7 1.5 1.7 1-fold
Oxaliplatin (mM) 1.1 0.4 1.0 0.2 1-fold
Ethacrynic acid (mM) 24.3 1.3 22.3 1.7 1-fold
Ga(NO3)3 (mM) 343.7 12.0 205.2 12.5 0.6-fold*
Camptothecin (nM) 226.4 1.1 137.1 19.1 0.6-fold**
Hydroxyurea (mM) 1.67 0.07 0.81 0.03 0.5-fold*
BSO (mM) 50 – 3.5 0.4 <0.1-fold*
* p < 0.05.
** p < 0.01.
*** p < 0.001.
P. Heffeter et al. / Biochemical Pharmacology 83 (2012) 1623–16331626inhibitor ethacrynic acid was observed. With regard to other
thiosemicarbazones (Table 2), the resistance of KB-1089(50 nM)
cells was independent from the presence of a gallium center in the
molecular structure. However, TD was found to be essential for the
resistance as KB-1089(50 nM) cells were distinctly cross-resistant
against all thiosemicarbazone derivatives, which are terminal
dimethylated (KP1550, KP1740 and KP1719), while no cross-
resistance against thiosemicarbazones lacking TD (KP1657 and
Triapine) was found.
3.2. Genomic characterization of KB-1089(50 nM) cells
To gain more insights into the cytogenetic alterations induced
by selection with KP1089, CGH experiments were performed. In
accordance to published data [22], KB-3-1 harbored multiple gains
and losses such as a loss of 4q, a gain in 1q12-21, and a very
prominent gain of 5p. Notably, KB-1089(50 nM) cells had
additional changes only in 2 chromosomes compared to KB-3-1
cells: loss of the complete chromosome 10 (data not shown) and
strong rearrangements of chromosome 16 (Fig. 2B). These changes
were exactly conﬁrmed by indirect CGH hybridization of a 1:1 mix
of KB-1089(50 nM) and KB-3-1 DNA on normal metaphase
chromosomes (data not shown). To investigate the changes with
higher resolution, array CGH (aCGH) analyses were performed. In
accordance to the CGH data, only a few and very distinct
alterations were observed in KB-1089(50 nM) as compared to
KB-3-1 cells. A reduced copy number of almost the whole
chromosome 10 in KB-1089(50 nM) cells with the exception of
the very terminal telomeric p-arm region was conﬁrmed (data not
shown). With regard to chromosome 16, the aCGH analysis
revealed that one copy of the complete q-arm was lost in the
KP1089-resistant cell line. Moreover, the very strong and distinct
amplicon was veriﬁed in the p-arm (Fig. 2C). The amplicon
consisted of two parts concerning the copy number alterations (log
two values are given in the right panel of Fig. 2C), one distal part
with an about 16-fold increase in the copy numbers of the MPV17L
and parts of the NDE1 gene and one high level ampliﬁed part (up to
>100-fold) harboring the MYH11, ABCC1, and ABCC6 genes
(Fig. 2C). To conﬁrm this amplicon in the KB-1089(50 nM) model,
FISH studies were performed on metaphase preparations of
parental and resistant cells. Parental KB-3-1 cells displayed an
unstable hyperdiploid to triploid karyotype with the ABCC1 BAC
probe localizing two to four copies of the ABCC1 gene. Three ofthese copies localized to the respective region at chromosomes 16
while the occasionally occurring additional copy was part of a
marker chromosome containing only a small amount of material
from chromosome 16 (Fig. 3A). In the KP1089-resistant subline
multiple small DNA particles were observed by DAPI staining
indicative for double minute chromosomes. FISH analysis demon-
strated that the extrachromosomal DNA contained ampliﬁed
sequences of ABCC1 as evidenced by colocalization with the ABCC1
BAC probe (Fig. 3A). In accordance to these data, enhanced ABCC1
expression was also detected on protein level as determined by
Western blot analyses (Fig. 3B). Furthermore, selection with
KP1089 was found to induce the expression of ABCC2 and ABCG2
(probably via epigenetic mechanisms), while drug selection had no
effects on ABCB1 and ABCC5 levels (data not shown).
3.3. Identiﬁcation of KP1089 as substrate of ABCC1 and ABCG2 but not
of ABCB1
As selection with KP1089 led to strong ampliﬁcation of the
ABCC1 gene and induced expression of ABCC1, ABCC2, and ABCG2,
it was investigated whether overexpression of these transporter
proteins is associated with resistance to KP1089. To this end, the
anticancer activity of KP1089 was tested in several cell lines, which
are characterized by speciﬁc ABC transporter (over)expression, in
comparison to their ABC transporter-negative chemosensitive
parental lines. As shown in Table 3, ABCC1 expression was
associated with signiﬁcantly increased IC50 values of the respective
resistance cell models GLC-4/adr (5.3-fold), HL60/adr (5.8-fold),
SW1573/2R120 (17.8-fold; high level ABCC1 expression), and
SW1573/2R160 (2.5-fold; low level ABCC1 expression). Also
ABCG2-transfected MDA-MB-231/bcrp cells displayed 3.8-fold
resistance in comparison to the vector control-transfected MDA-
MB-231/vc cells. With regard to ABCB1, no signiﬁcant impact was
found on the anticancer activity of KP1089. To conﬁrm that the
resistance of the KP1089-selected cell line is dependent on the
ABCC1 and ABCG2 transporter activity, the known ABCC1 inhibitor
cyclosporine A (CSA) and the ABCG2 modulator fumitremorgin C
(FTC) [17,23,24] were used. As shown in Fig. 4A, inhibition of
ABCC1 and ABCG2 distinctly sensitized KB-1089(50 nM) cells to
the anticancer activity of KP1089. Furthermore, combination of
CSA with FTC led to complete re-sensitation of KB-1089(50 nM)
cells. In cells speciﬁcally overexpressing ABCC1 (an experiment
using HL60/adr cells is shown as an example in Fig. 4B), ABCC1
Fig. 2. KP1089 resistance and genomic characterization of KB-1089(50 nM) cells. (A) Anticancer activity of KP1089 was tested in KB-3-1 and KB-1089(50 nM) cells by MTT assay
after 72 h drug incubation. Values given are means  SD of three experiments performed in triplicates. (B) Comparative genome hybridization (CGH) proﬁles of chromosomes 16. (C)
Array CGH results for total chromosome 16 of KB-1089(50 nM) (gray) in comparison to KB-3-1 (black) cells are shown in the left panel. The middle panel gives the gene view of the 16p
region speciﬁcally ampliﬁed in KB-1089 cells. Each dot indicates the position of one oligonucleotide and gray boxes the positions of genes within this region. The right panel gives the
quantiﬁcation of those oligonucleotide probes residing in the highly ampliﬁed region. All values are the log 2 ratios of means as compared to normal control DNA.
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resistance. In accordance with these results, KB-1089(50 nM) cells
displayed reduced accumulation of the ﬂuorescent ABCC1
substrate Calcein-AM and the ABCG2 substrate PhA, which could
be signiﬁcantly increased by coincubation with the inhibitors CSA
and FTC (Fig. 4C).
3.4. Role of GSH in the resistance against KP1089
Drug transport of the ABCC family members is known to be
GSH-dependent [25]. As shown in Fig. 5A, KB-1089(50 nM) cellswere characterized by distinctly lower basal GSH levels (2.6-fold)
in comparison to parental KB-3-1 cells. In both cell lines incubation
with BSO led to distinct depletion of the intracellular GSH pools [in
case of KB-1089(50 nM) even below the limit of detection (LOD)].
To assess the importance of the intracellular GSH pools for the
resistance of KB-1089(50 nM) cells, the impact of GSH depletion on
the activity of KP1089 was tested in 72 h vitality assays. Reduction
of GSH led to distinct re-sensitation of KB-1089(50 nM) as well as
HL60/adr cells to the anticancer activity of KP1089 (Fig. 5B and C).
Notably, BSO treatment also signiﬁcantly sensitized chemosensi-
tive KB-3-1 cells (Fig. 5D), which lack high ABC transporter
Table 2
Cross-resistance pattern of KB-1089(50 nM) cells: thiosemicarbazones. The signiﬁcance of resistance in comparison to the parental line has been calculated by Student’s t-test
using Graph Pad Prism Software.
Formula of the ligand Drug (nM) KB-3-1 KB-1089
IC50 SD IC50 SD Relative resistance
N
N
N
H
N
S
KP1089
Ga-complex
4.9 0.8 100 – 20-fold*
KP1550
metal-free ligand
26.7 2.6 100 – 3.7-fold*
N
N
N
H
N
S
KP1740
Ga-complex
360 25 2500 – 7-fold*
N
N
N
H
NH2
S
KP1657
Ga-complex
5300 60 6700 20 1-fold
N
N
N
H
NH2
S
NH2
Triapine
metal-free ligand
2800 20 2300 100 1-fold
N
N
N
H
N
S
NH2
KP1719
metal-free ligand
390 13 2500 – 6.4-fold*
* p < 0.001.
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the known ABCC1 substrate vinblastine where BSO treatment
sensitized KB-1089(50 nM) cells, only, but had no effect in KB-3-1
cells (Fig. 5E), corresponding to reports on other ABCC1-over-
expressing cell models [26,27]. This indicates that, in contrast to
vinblastine, the GSH pools are not only relevant for KP1089
transport by ABCC1 but might ABC transporter-independently
regulate the KP1089 responsiveness of cancer cells.
A possible conjugation of the KP1089 ligand with GSH in the
presence of GST was investigated using electrospray ionization
mass spectrometry (ESI-MS). Basically, the conjugation can takeTable 3
Impact of ABC-transporter-mediated drug resistance mechanisms on the activity of K
calculated by Student’s t-test using Graph Pad Prism Software.
Cell line IC50 KP1089 (nM) SD 
GLC-4 3.2 1.2 
GLC-4/adr 16.9 0.8 
HL60 0.6 0.06 
HL60/adr 3.5 1.0 
SW1573 2.8 0.7 
SW1573/2R120 50 0.9 
SW1573/2R160 7.0 1.0 
MDA-MB-231/vc 2.0 1.0 
MDA-MB-231/bcrp 7.5 0.9 
KB-3-1 4.6 1.8 
KBC-1 3.9 0.8 
* p < 0.05.
** p < 0.01.
*** p < 0.001.place via a GST-catalyzed oxidation of the thiosemicarbazone sulfur
atom with a GSH molecule leading to the formation of a disulﬁde
bond. CDNB was used as a positive control for GSH conjugation by
GST [28]. After incubation of CDNB with GSH and GST the ESI-MS
spectra in the negative ion mode showed a distinct peak at 472 m/z
according to the conjugation of CDNB with GSH. In contrast, no
KP1550-GSH conjugate (peak would be around 526 m/z) was
observable in these experiments (data not shown). This suggests
that GST is not able to catalyze the oxidative conjugation of KP1089
and GSH, which is in accordance to the lack of impact of the GST
inhibitor EA on the anticancer activity of KP1089 (Fig. S2).P1089. The signiﬁcance of resistance in comparison to the parental line has been
Relative resistance Resistance mechanism
– Parental
5.3-fold* ABCC1, MVP
– Parental
5.8-fold** ABCC1, ABCC5
– Parental
17.8-fold* ABCC1
2.5-fold** ABCB1, ABCC1
– Parental
3.8-fold** ABCG2
– Parental
0.8-fold ABCB1
Fig. 3. ABCC1 ampliﬁcation and overexpression induced by KP1089 selection. (A) Cytogenetic preparations of KB-3-1 and KB-1089(50 nM) cells were subjected to FISH
analysis with whole chromosome 16 paint (red) and an ABCC1 BAC probe (green). In the lower panel interphase nuclei of KB-1089(50 nM) cells are shown. DNA was
counterstained with DAPI. Expression of ABCC1 (B), ABCB1, ABCC2, and ABCG2 (C) in membrane-enriched fractions of the indicated cell lines was determined by Western
blotting. Ponceau-staining prooﬁng equal lane loading is shown in the Supplementary material (Fig. S1). One of the two immunoblots delivering comparable results is shown
representatively.
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Thiosemicarbazones are known for their promising anticancer
activity, which resulted in clinical studies of Triapine against
cancer [1,2]. However, despite promising activity against leukemia
[1,2], Triapine has proven ineffective against a variety of solid
malignancies [3–5]. Although an impact of multidrug-resistance
proteins (especially ABCB1) was suggested [6–8], the reasons for
this inactivity are widely unknown. Moreover, the impact ofintrinsic and acquired drug resistance on a-N-heterocyclic
thiosemicarbazones in general is so far rather unexplored and in
case of the highly cytotoxic terminal dimethylated derivatives
completely missing.
In this study, the new gallium thiosemicarbazone complex
KP1089 was identiﬁed as substrate for ABCC1 and ABCG2 but not
for ABCB1. Moreover, we discovered that the ABCC1- and ABCG2-
mediated resistance is based on TD of the thiosemicarbazone
structure. Thus, no cross-resistance of KP1089-selected cells
Fig. 4. Impact of MDR modulators on the cytotoxic potential of KP1089. (A) KB-1089(50 nM) and KB-3-1 cells were treated with KP1089 in combination with the ABCC1
inhibitor CSA (1 mM), the ABCG2 modulator FTC (10 mM) or a combination of CSA and FTC. Signiﬁcance of difference to the respective KP1089-treated groups was calculated
by 2-way-ANOVA (with Bonferroni post correction) using Graph Pad Prism Software. (B) HL60/adr, and HL60 cells were incubated with KP1089 and co-administered with the
ABCC1 inhibitors verapamil (10 mM) and CSA (1 mM). After 72 h drug treatment vitality was determined by MTT assay. Values given are means  SD of two experiments
performed in triplicate. Signiﬁcance of difference to the respective KP1089-treated groups was calculated by 2-way-ANOVA (with Bonferroni post correction) using Graph Pad Prism
Software. (C) The ABCC1 and ABCG2 transport activity in KB-1089(50 nM) cells was determined by Calcein-AM and PhA assays, respectively. CSA (1 mM) and FTC (10 mM) were used
as respective inhibitors. *Signiﬁcant difference from untreated KB-1089(50 nM) cells is p < 0.05 calculated by Student’s t-test using Graph Pad Prism Software.
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especially of interest, as terminal dimethylated thiosemicarba-
zones exhibit an about 1000-fold increased anticancer activity in
comparison to thiosemicarbazones without TD [11,12]. So far, the
mechanisms underlying this enhanced activity are widely
unknown and the matter of ongoing evaluations. Such, KP1089
has been recently tested against a panel of 60 cell lines as part of
the in vitro anticancer-screening services provided by the National
Cancer Institute (NCI) and, subsequently, has been selected by theNCI for further in vivo evaluation due to its interesting activity
proﬁle which differs from other thiosemicarbazones (unpublished
results). Also the here presented impact of ABCC1 indicates that
KP1089 distinctly differs from other thiosemicarbazones lacking
TD such as KP1657 or Triapine.
In general, the inﬂuence of ABCC1 on KP1089 in contrast to
thiosemicarbazones without TD is rather unexpected and difﬁcult
to explain as the physico-chemical properties of these molecules
are expected to be widely similar [12,29]. A possible explanation
Fig. 5. The role of GSH in the anticancer activity of KP1089. (A) Intracellular GSH levels of KB-3-1 and KB-1089 were detected by LC–MS in cytosolic lysates of untreated cells
and after 20 h exposure to BSO (25 mM) as described in the Material and Methods Section. (B) HL60/adr, KB-1089(50 nM) (C), and KB-3-1 cells were treated with KP1089 after
20 h preincubation with the gamma-glutamylcysteine synthetase inhibitor BSO. The BSO-induced increase in sensitivity (-fold change) to KP1089 at the IC50 concentrations is
given in the brackets Values given are means  SD of two experiments performed in triplicate. Signiﬁcance of difference to the respective KP1089-treated groups was calculated by
2-way-ANOVA (with Bonferroni post correction) using Graph Pad Prism Software. (D) Impact of GSH depletion on the anticancer activity of vincristine against KB-1089(50 nM) and
KB-3-1 cells was determined as described above. Signiﬁcance of difference to the respective vincristine-treated groups was calculated by 2-way-ANOVA (with Bonferroni post
correction) using Graph Pad Prism Software.
P. Heffeter et al. / Biochemical Pharmacology 83 (2012) 1623–1633 1631might be enhanced lipophilicity of terminal dimethylated thiosemi-
carbazones in comparison to compounds without TD as it has been
shown in case of dipyridylketone thiosemicarbazones [30]. En-
hanced lipophilicity might be associated with stronger afﬁnity to
hydrophobic binding sites in the ABCC1 molecule [31] and, thus,
more effective drug export. Another explanation might be a
difference in the metabolization of terminal dimethylated thiose-
micarbazones. ABCC subfamily members mainly transport organic
anions after their conjugation to hydrophilic ligands such as GSH,glucoronic acid, or sulfate [25] and, such, are essential in the
excretion of phase II detoxiﬁcation products [32]. Consequently,
ABCC1 might not transport KP1089 directly but one of its
metabolites. The transport of KP1089 conjugates would be
comparable to observations with other metal drugs (e.g. cisplatin,
arsenic trioxide), where transport by ABCC family members was
shown for their GSH conjugates only [9]. Also in case of KP1089, the
intracellular GSH pools turned out to be important. Such, depletion of
the intracellular GSH levels sensitized cells against KP1089 in
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chemo-sensitive parental cells) and KB-1089(50 nM) cells were per
se very sensitive to GSH depletion. This might be explained by the
lower intracellular GSH pools of KB-1089(50 nM) cells in comparison
to KB-3-1 cells, which has been also reported for other ABCC1-
overexpressing cell models such as GLC-4/adr [21] or HL60/adr cells
[33]. In addition, collateral sensitivity to BSO treatment was shown
for other ABCC1-overexpressing cell lines [34]. This further supports
the assumption that the ABCC1-mediated resistance against KP1089
is GSH-dependent. However, in cell-free settings no GSH-KP1089
conjugate formation was observed (even in the presence of GST) and,
accordingly, a GST inhibitor did not re-sensitize KB-1089(50 nM)
cells to KP1089 treatment. Consequently, a possible GSH conjugation
to KP1089 has to be mediated by other mechanisms. Alternatively,
GSH conjugation is not always necessary for ABCC-mediated drug
transport. Lipophilic compounds can be co-transported together
with unbound GSH as it has been reported for vincristine or
doxorubicin [25,31]. To gain more insights into the interaction of
KP1089 with GSH further studies are of interest and mass
spectrometry-based assays are currently established to monitor
the intracellular metabolism of KP1089 in resistant and chemosen-
sitive cancer cells.
With regard to other thiosemicarbazones, the knowledge on
resistance development is, as already mentioned above, rather
sparse. So far, only one murine L1210 cell model with acquired
resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemi-
carbazone (MAIQ; which has no TD; Fig. 1) has been reported
[6,35]. This cell line, which was cross-resistant to Triapine as well
as etoposide, daunomycin, and vinblastine, was shown to harbor
several resistance-mediating mechanisms including (1) enhanced
activity of the thiosemicarbazone target ribonucleotide reductase,
(2) multiple metabolic alterations such as overexpression of
disulﬁde isomerases, and (3) overexpression of the mdr1, mdr3 as
well as the mrp gene [6,35]. Furthermore, Rappa et al. reported
resistance of mdr1- as well as mrp-transfected murine cancer cells
against Triapine [6]. Also in clinical trials an impact of the patients’
mdr genotype on the clinical outcome was suggested [7,8]. The
observation of ABCC1-mediated resistance by Rappa et al. [6] is of
interest, as we did not observe any cross-resistance of KB-
1089(50 nM) cells against Triapine, which suggests that the
activity of this thiosemicarbazone is not affected by ABCC1 and
ABCG2 expression. With respect to ABCB1, it is noteworthy that in
course of a bioinformatic evaluation recently performed on the NCI
screening dataset several thiosemicarbazones came in the focus of
interest because of their enhanced activity in ABCB1-positive
background [36–38]. Detailed structure-activity-studies on isatin-
b-thiosemicarbazones further revealed that these ABCB1-target-
ing properties are most prominent in derivatives with a para-
substituted terminal 40-phenyl moiety like 1-isatin-4-(40-methox-
yphenyl)-3-thiosemicarbazone (NSC73306; Fig. 1) [37]. In addition
to ABCB1, NSC73306 was shown to modulate the activity of ABCG2
(although this transporter did not protect cells from NSC73306
activity) but not the activity of ABCC1, ABCC4, and ABCC5 [39].
Overall, our data indicate that in case of thiosemicarbazones
small structural modiﬁcations can have very pronounced effects on
the resistance proﬁle as well as the interaction of this compound
class with ABC transporters. Consequently, a more detailed
investigation of thiosemicarbazones with respect to ABC trans-
porters might be not only of interest for the clinical usability of
these compounds but also for the improvement of the under-
standing of ABC transporter-mediated drug resistance in general.
In conclusion, this study represents the ﬁrst report on the
pronounced impact of TD on the resistance proﬁle of a-N-
heterocyclic thiosemicarbazones and their gallium complexes.
Moreover, we were able to demonstrate that, although terminal
dimethylated thiosemicarbazones are substrates for ABCC1 andABCG2, these compounds are still more active in cells harboring
these efﬂux pumps than thiosemicarbazones lacking TD. This
makes the terminal dimethylated thiosemicarbazones of interest
for further (pre)clinical evaluation.
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